General Toxicity Notes
Blood levels most often the best guide to therapy. Half-life may be prolonged in heart failure or with reduced hepatic blood flow.
Half-Life (Normalesrd) Hours
8-14/20-39
Plasma Protein Binding %
51-71
Volume Of Distribution L/Kg
4.5-5.4
Dose For Normal Renal Function
50-100 mg q12h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [B]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Bailie GR, Waldek S. Pharmacokinetics of flecainide in a patient undergoing continuous ambulatory peritoneal dialysis. J Clin Pharm Ther. 1988; 13: 121-4. [PMID: 3134365] / Borgeat A, Biollaz J, Freymond B, Bayer-Berger M, Chiolero R. Hemofiltration clearance of flecainide in a patient with acute renal failure. Intensive Care Med. 1988; 14: 236-7. [PMID: 3132493] / Evers J, Eichelbaum M, Kroemer HK. Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death? Ther Drug Monit. 1994; 16: 349-51. [PMID: 7974623] / Forland SC, Burgess E, Blair AD, Cutler RE, Kvam DC, Weeks CE, et al. Oral flecainide pharmacokinetics in patients with impaired renal function. J Clin Pharmacol. 1988; 28: 259-67. [PMID: 3129455] / Williams AJ, McQuinn RL, Walls J. Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther. 1988; 43: 449-55. [PMID: 3128417]
Toxicity Notes
Excretion enhanced in acid urine.